Cancer Chemotherapy and Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 3, 2013, Pages 263-278

  Koren, Gideon ^a   Carey, Nathalie ^a   Maxwell, Cynthia ^a   Nulman, Irena ^a   Gagnon, Robert ^a   Senikas, Vyta ^a  

^a NONE   (Canada)

Author keywords

Antineoplastic agents; Cancer; Chemotherapy; Neoplasms; Pregnancy; Pregnancy prevention

Indexed keywords

ALKALOID; ANTHRACYCLINE; ANTIMETABOLITE; ARABINOSIDE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; METHOTREXATE; MITOXANTRONE; PACLITAXEL; RITUXIMAB; VINCRISTINE;

ARTICLE; BREAST CANCER; BREAST FEEDING; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CHORIOCARCINOMA; CLINICAL PRACTICE; DRUG DOSE REGIMEN; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; FEMALE; FETUS RISK; FOLLOW UP; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MATERNAL RISK; MATERNAL WELFARE; MATERNAL WELLBEING; MEDICAL DECISION MAKING; MEDICAL ETHICS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; ORGANOGENESIS; OVARY CANCER; PANCREAS TUMOR; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TERMINATION; PREGNANT WOMAN; PREVENTIVE MEDICINE; PROMYELOCYTIC LEUKEMIA; PUERPERIUM; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SMALL CELL LUNG CANCER; SYSTEMATIC REVIEW (TOPIC); TERATOLOGICAL RISK; TERATOLOGY; THIRD TRIMESTER PREGNANCY; WELLBEING;

EID: 84883800868     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30999-3     Document Type: Article

References (88)

1. Cancer Care Ontario, Cancer in young adults in Canada 2006, Cancer Care Ontario, Toronto, May 2006. Available at:, Accessed December 27, 2012. http://www.cancer.ca.
2. Santucci A.K., Gold M.A., Akers A.Y., Borrero S., Schwarz E.B. Women's perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol 2009, 88:64-69.
3. RevAid [website] 2013, Available at:, Accessed January 3. http://www.revaid.ca/revaid.
4. Pereg D., Koren G., Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev 2008, 34:302-312.
5. Koren G., Lishner M., Santiago S. The Motherisk guide to pregnancy and lactation 2005, Motherisk Program, Toronto. 2nd ed.
6. Azim H.A., Peccatori F.A. Managing cancer during pregnancy: what evidence do we have?. Pol Arch Med Wewn 2011, 121:29-34.
7. Leslie K.K. Chemotherapy and pregnancy. Clin Obstet Gynecol 2002, 45(1):153-164.
8. Koren G., Pastuszak A., Ito S. Drugs in pregnancy. N Engl J Med 1998, 338(16):1128-1137.
9. Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol 2011, 205:285-294.
10. iPledge [website] 2013, Available at:, Accessed January 3. https://www.ipledgeprogram.com/Default.aspx.
11. Moore K.L. The developing human: clinically oriented embryology 1988, 131. W.B. Saunders, Philadelphia. 4th ed.
12. Buhimschi C.S., Weiner C.P. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol 2009, 113(1):166-188.
13. Laffitte E., Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 2004, 3(1):47-56.
14. Thalidomide Victims Association of Canada. The Canadian tragedy 2011, Available at:, Accessed December 27, 2012. http://www.thalidomide.ca/the-canadian-tragedy.
15. CBC News. In depth health: thalidomide Nov 22, 2007, Available at, Accessed December 27, 2012. http://www.cbc.ca/news/background/health/thalidomide.html.
16. Pavlidis N.A. Coexistence of pregnancy and malignancy. Oncologist 2002, 7:279-287.
17. Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004, 5:283-291.
18. VanCalsteren K., Verbesselt R., Ottevanger N., Halaska M., Heyns L., VanBree R., et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 2010, 89:1338-1345.
19. Doll D.C., Ringenberg Q.S., Yarbro J.W. Antineoplastic agents and pregnancy. Semin Oncol 1989, 16:337-346.
20. Cardonick E., Usmami A., Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy. Am J Clin Oncol 2010, 33:221-228.
21. VanCalsteren K., Heyns L., DeSmet F., VanEycken L., Gziri M.M., VanGemert W., et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010, 28:683-689.
22. Missailidis S. Anticancer therapeutics 2008, John Wiley & Sons, Ltd, Chichester, GB. 1st ed.
23. Aviles A., Dfaz-Maqueo J.C., Talavera A., Guzman R., Garcia E.L. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991, 36(4):243-248.
24. Greenberg L.H., Verdes P., Tanaka K.R. Congenital anomalies probably induced by cyclophosphamide. JAMA 1964, 188(5):423-426.
25. Toledo T.M., Harper R.C., Moser R.H. Fetal effects duringcyclophosphamide and irradiation therapy. Ann Intern Med 1971, 74:87-91.
26. Murray C.L., Reichert J.A., Anderson J., Twiggs L.B. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. JAMA 1984, 252:2607-2608.
27. Kirshon B., Wasserstrum N., Willis R., Herman G.E., McCabe E.R. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988, 72(3 pt2):462-464.
28. Zemlickis D., Lishner M., Erlich R., Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 1993, 13(3):139-143.
29. Hahn K.M., Johnson P.H., Gordon N., Kuerer H., Middleton L., Ramirez M., et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006, 106:1219-1226.
30. Berry D.L., Theriault R.L., Holmes F.A., Parisi V.M., Booser D.J., Singletary S.E., et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999, 17(3):855-861.
31. Ring A.E., Smith I.E., Jones A., Shannon C., Galani E., Ellis P.A. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005, 23:4192-4197.
32. Aviles A., Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymph 2001, 2(3):173-177.
33. Nakajima W., Ishida A., Takahashi M., Hirayama M., Washino N., Ogawa M., et al. Good outcome for infant of mother treated with chemotherapy for Ewing sarcoma at 25 to 30 weeks' gestation. J Pediatr Hematol Oncol 2004, 26:308-311.
34. Merimsky O., LeChevalier T., Missenard G., Lepechoux C., Cojean-Zelek I., Mesurolle B., et al. Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester. Ann Oncol 1999, 10:345-350.
35. Lishner M., Zemlickis D., Degendorfer P., Panzarella T., Sutcliffe S.B., Koren G., et al. Maternal and foetal outcome following Hodgkin's disease in pregnancy. Br J Cancer 1992, 65:114-117.
36. Giacalone P.L., Laffargue F., Benos P., Rousseau O., Hedon B. Cisplatin neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervix. Br J Obstet Gynaecol 1996, 103(9):932-934.
37. Caluwaerts S., VanCalsteren K., Mertens L., Lagae L., Moerman P., Hanssens M., et al. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. Int J Gynecol Cancer 2006, 16:905-908.
38. Benhaim Y., Pautier P., Bensaid C., Lhomme C., Haie-Meder C., Morice P. Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression. Eur J Obstet Gynecol Reprod Biol 2008, 136(2):267-268.
39. Palaia I., Pernice M., Graziano M., Bellati F., Panici P.B. Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. Am J Obstet Gynecol 2007, 197(4):e5-e6.
40. Kluetz P.G., Edelman M.J. Successful treatment of small cell lung cancer during pregnancy. Lung Cancer 2008, 61(1):129-130.
41. Ferrandina G., Distefano M., Testa A., DeVincenzo R., Scambia G. Management of an advanced ovarian cancer at 15 weeks of gestation: Case report and literature review. Gynecol Oncol 2005, 97:693-696.
42. Karimi-Zarchi M., Behtash N., Modares Gilani M. Good pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for ovarian immature teratoma: a case report and literature review. Arch Gynecol Obstet 2008, 277:75-78.
43. Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology 1978, 17(3):353-357.
44. Bawle E.V., Conard J.V., Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998, 7:51-55.
45. Buckley L.M., Bullboy C.A., Leichtman L., Marquez M. Multiple congenital anomalies associated with weekly low dose methotrexate treatment of the mother. Arthritis Rheum 1997, 40:971-973.
46. Diniz E.M., Corradini H.B., Ramos J.L., Brock R. Effect of the fetus of methotrexate (amethopterin) administered to the mother. Presentation of a case [article in Portuguese]. Rev Hosp Clin Fac Med Sao Paulo 1978, 33:286-290.
47. Milunsky A., Greaf J.W., Gaynor M.F. Methotrexate induced congenital malformations. J Pediatr 1968, 72:790-795.
48. Powell H.R., Ekert H. Methotrexate induced congenital malformations. Med J Aust 1971, 2:1076-1077.
49. Dara P., Slater L.M., Armentrout S.A. Successful pregnancy during chemotherapy for acute leukemia. Cancer 1981, 47:845-846.
50. Feliu J., Juarez S., Ordonez A., Garcia-Paredes M.L., Gonzalez-Baron M., Montero J.M. Acute leukemia and pregnancy. Cancer 1988, 61:580-584.
51. Addar M.H. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: a case report. J Obstet Gynaecol Can 2004, 26:1001-1003.
52. Kozlowski R.D., Steinbrunner J.V., MacKenzie A.H., Clough J.D., Wilke W.S., Segal A.M. Outcome of first trimester exposure to low dose methotrexate in eight patients with rheumatic disease. Am J Med 1990, 88:589-592.
53. Gurumurthy M., Koh P., Sing R., Bhide A., Satodia P., Hocking M., et al. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. J Perinatol 2009, 29:63-65.
54. Valappl S., Kurkar M., Howell R. Outcome of pregnancy in women treated with all-trans retinoic acid: a case report and review of literature. Hematology 2007, 12(5):415-418.
55. Niedermeier D.M., Frei-Lahr D.A., Hall P.D. Treatment of acute myeloid leukemia during the second trimester of pregnancy. Pharmacotherapy 2005, 25:1134-1140.
56. Siu B.L., Alonzo M.R., Varga T.A., Ferich A.L. Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 2002, 12:399-402.
57. Achtari C., Hohlfield P. Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obstet Gynecol 2000, 183:511-512.
58. Claahsen H.L., Semmekrot B.A., van Dongen P.W., Mattijssen V. Successful outcome after exposure to idarubicin and cytosine-arabinoside during second trimester of pregnancy-a case report. Am J Perinatol 1998, 15:295-297.
59. Matsuo K., Shimoya K., Ueda S., Wada K., Koyama M., Murata Y. Idarubicin administered during pregnancy: its effect on the fetus. Gynecol Obstet Invest 2004, 58:186-188.
60. Mir O., Berveiller P., Goffinet F., Treluyer J.M., Serreau R., Goldwasser F., et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010, 21:425-433.
61. Gonzalez-Angulo A.M., Walters R.S., Carpenter R.J., Ross M.I., Perkins G.H., Gwyn K., et al. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 2004, 5(4):317-319.
62. Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., et al. The effects of imatinib on pregnancy outcome. Blood 2008, 111:5505-5508.
63. Cole S., Kantarjian H., Ault P., Cortes J.E. Successful completion of pregnancy in patient with CML without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma 2009, 9(4):324-327.
64. Chakravarty E.F., Murray E.R., Kelman A., Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011, 117(5):1499-1506.
65. Pentheroudakis G. Cancer and pregnancy. Ann Oncol 2008, 19(5):v38-v39.
66. Pentheroudakis G., Orecchia R., Hoekstra H.J. Pavlidis N; ESMO Guidelines Working Group.et al. Cancer, fertility and pregnancy: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(5):v266-v273.
67. Lishner M. Cancer in pregnancy. Ann Oncol 2003, 14(3):iii31-iii36.
68. Pereg D., Koren G., Lishner M. The treatment of Hodgkin and non-Hodgkin's lymphoma. Haematologica 2007, 92:1230-1237.
69. Shapira T., Pereg D., Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev 2008, 22(5):247-249.
70. Ito S. Drug therapy for breast-feeding women. N Eng J Med 2000, 343:118-126.
71. Van Herwaarden A.E., Wagenaar E., Merino G., Jonker J.W., Rosing H., Beijnen J.H., et al. Multidrug transporter ABCG2/Breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 2007, 27(4):1247-1253.
72. Egan P.C., Costanza M.E., Dodion P., Egorin M.J., Bachur N.R. Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep 1985, 69:1387-1389.
73. Gilad B.B., Joseph M. Cisplatin excretion in human milk. J Natl Cancer Inst 1992, 84:451-452.
74. De Vries E.G., van der Zee A.G., Uges D.R., Sleijfer D.T. Excretion of platinum into breast milk. Lancet 1989, 1(8636):497.
75. Urien S., Brain E., Bugat R., et al. Pharmacokinetics of platinum after oral or intravenous cisplatin; a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 2005, 55:55-60.
76. Amato D., Niblett J.S. Neutropenia from cyclophosphamide in breast milk. Med J Aust 1977, 1(11):383-384.
77. James I.D. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Natl Med Assoc 1979, 71:165-166.
78. Wiernik P.H., Duncan J.H. Cyclophosphamide in human milk. Lancet 1971, 1:912.
79. Azuno Y., Kaku K., Fujita N., Okubo M., Kaneko T., Matsumoto N. Mitoxantrone and etoposide in breast milk. Am J Hematol 1995, 48:131-132.
80. Kronenberger R., Schleyer E., Bornhauser M., Ehninger G., Gattermann N., Blum S. Imatinib in breast milk. Ann Hematol 2009, 88:1265-1266.
81. Ali R., Ozkalemkas F., Kimya Y., Koksal N., Ozkocaman V., Gulten T., et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009, 280:169-175.
82. Russell M.A., Carpenter M.W., Akhtar M.S., Lagattuta T.F., Egorin M.J. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007, 27:241-243.
83. Gambacorti-Passerini C.B., Tornaghi L., Marangon E., et al. Imatinib concentrations in human milk. Blood 2007, 109:1790.
84. Johns D.G., Rutherford L., Leighton P.C., Vogel C.L. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972, 112:978-980.
85. Tanaka T., Walsh W., Verjee Z., et al. Methotrexate use in a lactating woman with an ectopic pregnancy [abstract]. Birth Defects Res A Clin Mol Teratol 2009, 85:494.
86. Nulman I., Laslo D., Fried S., Uleryk E., Lishner M., Koren G. Neurodevelopment of children exposed in utero to treatment of maternal malignancy. Br J Cancer 2001, 85:1611-1618.
87. Azim H.A., Paclidis N., Peccatori F.A. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrne, targeted agents and immunotherapy during pregnancy. Part I and II. Cancer Treat Rev 2010, 36:101-121.
88. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.